A Mother's Hope Dashed by a $2 Million Price Tag

Ciji Green's heart leaped with joy when she discovered a gene therapy could potentially save her daughter, Maisie's, life. Diagnosed with spinal muscular atrophy, a severe condition where muscles progressively waste away, Maisie's prognosis without treatment was grim, with many children not surviving past their second birthday. The treatment, approved in 2019, offered a miracle. However, there was a catch—it was priced at an astronomical $2 million, and Green's insurer declined to cover it.

“It’s infuriating to know there’s a solution, yet realize that you have no means to access it,” Green expressed, feeling that she was inevitably watching her daughter slip away.

The Expensive Reality of Life-Saving Drugs

Gene therapies represent a new era of medical breakthrough, often targeting rare illnesses with limited treatment avenues. Unfortunately, as these treatments extend toward more prevalent illnesses, they pose a substantial challenge to the U.S. healthcare infrastructure.

Jonathan Gruber, an economist involved in the Affordable Care Act's development, likened the surge of expensive therapies to an impending tidal wave, threatening to submerge employer-sponsored health plans.

Currently, over 300 costly gene therapies are in various stages of clinical trials, some aimed at conditions affecting millions. Employers providing health insurance might soon face the dilemma of covering these exorbitant treatments—an unaffordable prospect for many.

Gruber points out a critical issue: “Many American companies are self-insured, effectively footing their own healthcare bills. These entities, comprising about two-thirds of American-insured employees, must choose between financial ruin and refusing coverage to employees in dire need.”

The High Cost of Progress

Sarepta Therapeutics, led by CEO Doug Ingram, is among the companies charging millions for their gene therapy solutions. Their treatment for Duchenne muscular dystrophy, a disease that severely weakens muscles, costs several million dollars but could be the only hope for slowing down the disease's progression.

Ingram acknowledges the formidable challenges; their initial challenge was safely producing the therapy. It required more manufacturing capacity than was globally available at the time, along with billions in investment to bring the therapy into existence.

Facing Financial Strain

Mike Poore, the CEO of Missouri’s nonprofit hospital system Mosaic Life Care, experienced firsthand the strain of insulin treatments, as Mosaic decided their insurance plan would exclude such therapies to avoid raising employee premiums drastically.

When an employee's twins needed a $4.2 million treatment for SMA, denied by the company health plan, public outcry turned personal, with Poore and his family receiving threats. Eventually, Medicaid was approached to cover the twins' treatment.

Poore considers this a forewarning of what's to come, noting the seemingly endless rise in drug prices.

Addressing the Cost Dilemma

Neither the insurers denying coverage nor the pharmaceutical companies setting steep prices are seen as villains. Gruber argues that society needs to acknowledge the breakthrough yet expensive treatments and collaborate on absorbing these costs, potentially needing government intervention for cost-sharing or negotiation.

Ingram envisions prices lowering through increased manufacturing expertise and streamlined regulations. The current process of developing a therapy averages over a decade and nearly $3 billion, with a meager success probability.

Hope Restored for Maisie

Ciji Green, determined to save Maisie, turned to public fundraising and appealed directly to her insurance company. Eventually, her persistence led to success—the insurer agreed to fund Maisie's Zolgensma therapy in 2019.

The impact of receiving Zolgensma was profound, as Maisie, expected not to survive past age 2, thrived to attend school and excel academically, despite ongoing physical challenges.

For Green and her family, the gene therapy proved to be nothing short of miraculous.